• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Other Infectious Diseases - Pipeline Review, H2 2012 Product Image

Other Infectious Diseases - Pipeline Review, H2 2012

  • Published: October 2012
  • 49 pages
  • Global Markets Direct

Other Infectious Diseases – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Other Infectious Diseases - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Other Infectious Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Infectious Diseases. Other Infectious Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Infectious Diseases.
- A review of the Other Infectious Diseases products under READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Other Infectious Diseases Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Other Infectious Diseases 8
Other Infectious Diseases Therapeutics under Development by Companies 10
Other Infectious Diseases Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Other Infectious Diseases Therapeutics – Products under Development by Companies 17
Other Infectious Diseases Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Other Infectious Diseases Therapeutics Development 19
Novabiotics Ltd 19
Other Infectious Diseases – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
doxycycline - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
cefmetazole sodium - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Kanamycin + Metronidazole + Cefmetazole - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Palivizumab + Ribavirin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Vancomycin + Cefalexin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Ebola Vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
chlorhexidine gluconate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
streptomycin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Neulasta + Carboplatin + Paclitaxel - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
carnosine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Recombinant Modified Vaccinia Ankara Based Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cholera Toxin B - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
azithromycin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
povidone-iodine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
telithromycin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Drug For Polymicrobial Infections - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Other Infectious Diseases Therapeutics - Dormant Products 45
Other Infectious Diseases – Product Development Milestones 46
Featured News & Press Releases 46
Jun 25, 2010: Soligenix Announces Publication Of Positive Data Of RiVax Against Ricin Toxin In Vaccine 46
Sep 07, 2007: Totect approved in the United States 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products Under Development for Other Infectious Diseases, H2 2012 8
Products under Development for Other Infectious Diseases – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Novabiotics Ltd, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Other Infectious Diseases Therapeutics – Dormant Products 45

List of Figures
Number of Products under Development for Other Infectious Diseases, H2 2012 8
Products under Development for Other Infectious Diseases – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos